What is Kiora Pharmaceuticals Inc (KPRX) stock price today?

Kiora Pharmaceuticals Inc (KPRX) currently trades at $2.44 per share. The stock has a market capitalization of $10.53M and a P/E ratio of —x.

Is KPRX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Kiora Pharmaceuticals Inc has a Smart Value Score of 37/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -4.14.

Is Kiora Pharmaceuticals Inc financially healthy?

Kiora Pharmaceuticals Inc's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -4.14 places it in the distress.

KPRX

Kiora Pharmaceuticals Inc

NASDAQ: KPRX · HEALTHCARE · BIOTECHNOLOGY

$2.44

+3.83% today

Updated 2026-05-01

Market cap

$10.53M

P/E ratio

—

P/S ratio

0.14x

EPS (TTM)

$-2.64

Dividend yield

—

52W range

$2 – $4

Volume

0.6M

Market cap

$10.53M

P/E ratio

—

P/S ratio

0.14x

EPS (TTM)

$-2.64

Dividend yield

—

52W range

$2 – $4

Volume

0.6M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-4.1

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →204 stocks currently score above 75

Price targets

Analyst target

$12.00

+391.80%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.02x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -4.14 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-2.26M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$16.00M	$0.00	$0.00
Net income	$-13.58M	$-12.51M	$3.59M	$-10.84M	$-6.52M
EPS	—	—	—	—	$-2.64
Free cash flow	$-10.43M	$-9.56M	$8.55M	$-10.07M	$-2.26M
Profit margin	—	—	22.47%	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
KPRX	$10.53M	37	4.3	3.0	5.0	6.5	—	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-41.61%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-26.29%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.35%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Kiora Pharmaceuticals Inc trades at $2.44. Our Smart Value Score of 37/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -4.14, it sits in the distress.

Frequently asked questions

What is Kiora Pharmaceuticals Inc's stock price?

Kiora Pharmaceuticals Inc (KPRX) trades at $2.44.

Is Kiora Pharmaceuticals Inc overvalued?

Smart Value Score 37/100 (Grade D, Sell).

What is the price target of Kiora Pharmaceuticals Inc (KPRX)?

The analyst target price is $12.00, representing +391.8% upside from the current price of $2.44.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-4.14 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.kiorapharma.com

Quick metrics

P/S ratio0.14x

ROE-51.70%

Beta-0.77

50D MA$2.16

200D MA$2.37

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.6M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

KPRX vs LLY →KPRX vs JNJ →KPRX vs ABBV →Stock screener →